peptide, endothelin-1 [6], a more potent endotheliumBackground derived vasoconstrictor and pressor agent even than angiotensin II, was of major interest to the cardiovascular Until relatively recently, the vascular endothelium was thought to act as little more than a passive barrier to research community, and followed closely on the identification of the endothelium-derived relaxing factor (EDRF) diffusion. However, in the last few years, with the discovery of prostacyclin, nitric oxide and endothelin-1, a central role as nitric oxide [7] . At this early stage it was difficult to gain access to more than small quantities of synthetic has emerged for the endothelium in the regulation of vascular smooth muscle cell tonus and growth, immunologendothelin-1. However, it was clear that local infusion techniques could allow delineation of the vascular effects of ical reactivity, blood coagulation and lipid metabolism. This field of research has matured rapidly ( Figure 1 ) and, in a endothelin-1 more clearly, with greater safety, and with lower doses, than would be the case with systemic dosing. recent foresight exercise on behalf of the British Heart Foundation, Medical Research Council and Wellcome Trust
In collaboration with Dr John Clarke and Professor Attilio Maseri at the Royal Postgraduate Medical School, we began [1], the vascular endothelium was identified as the area commanding the highest priority in cardiovascular research clinical pharmacology studies at St George's Hospital in London in 1988, and our first pharmacodynamic observations over the next 10 years.
My own interest in this area originally developed while were published the following year [8] . Subsequent progress in endothelin research [9, 10] has working in the MRC Blood Pressure Unit in Glasgow. Observations in the first clinical trial of a renin inhibitor in maintained an extremely rapid pace such that we were able to perform the first human pharmacology studies with an man suggested the functional importance of a vascular reninangiotensin system [2] and, later, at St George's Hospital in inhibitor of endothelin generation, phosphoramidon, in 1992 and with an endothelin receptor antagonist, BQ-123, London I was able to show this by combining forearm plethysmography techniques with brachial artery infusions in 1993. Indeed, after only 8 years, the clinical development of drugs targeting the 'endothelin system' in cardiovascular of locally active doses of angiotensin I, angiotensin II, bradykinin and angiotensin converting enzyme (ACE) disease is now well advanced [11] . The first major clinical study in heart failure patients was reported in 1995 [12] and inhibitors [3, 4] . Surprisingly, these studies demonstrated in vivo that the endothelium of the forearm resistance vessels phase III trials should begin shortly. From a combination of fundamental and applied research it has become apparent has a considerable capacity to generate angiotensin II locally, equivalent to that of the pulmonary circulation [4, 5] .
that the 'endothelin system' is of central importance to the maintenance of normal cardiovascular function in healthy The discovery in 1988 of the novel 21 amino acid man and that endothelin-1 is likely to be a key mediator in the pathophysiology of cardiovascular disease. The main aim of this paper is to review current knowledge of the endothelin system; particularly its physiological function in the cardiovascular system and its role in cardiovascular disease. Although I will focus on human pharmacology and physiology, and in particular on the work of our group in Edinburgh, it must be recognised that all of the major advances in clinical research have depended critically on the identification and development of selective pharmacological probes through work on animal and isolated tissues. A subsidiary aim of this review is to demonstrate that clinical pharmacology studies can provide a critical contribution to our understanding of human cardiovascular physiology and pathophysiology, and to the process of early drug development and identification of suitable therapeutic targets. of porcine aortic endothelial cells [6] , it is now recognised remains unclear whether intracellular stored peptide represents an important pool available for rapid release and, to be a member of a family comprising three isoforms [13]: endothelin-1, endothelin-2 and endothelin-3 (Figure 2) . currently, regulation of endothelin synthesis is thought to be primarily at the level of gene transcription, with de novo Each isoform contains 21 amino-acids, two intra-chain disulphide bonds constraining overall structure, and a production and release occurring in response to endothelial cell stimulation. A large number of factors have now been conserved C-terminal sequence necessary for biological activity [13] . This structure is unique among the mammalian shown to increase endothelin-1 synthesis ( Figure 3 ): these include vasoactive hormones, inflammatory mediators and peptides but is shared by the sarafotoxins, snake venom peptides from the Israeli burrowing asp, Actractaspis engadphysico-chemical factors such as altered vascular shear stress and hypoxia. Other factors -including nitric oxide, nitric densis, one of which, sarafotoxin S6c, has proved particularly valuable as a pharmacological probe. While there is evidence oxide donor drugs, natriuretic peptides and the dilator prostanoids-serve to inhibit endothelin-1 generation by that endothelin-2 may possibly function as a mediator in the kidney, and endothelin-3 may act as mediator in the promoting production of cyclic GMP or cyclic AMP [10] . The initial product of the human endothelin-1 gene is gut and nervous system, endothelin-1 is the major isoform generated in blood vessels and appears to be of preproendothelin-1, a peptide of 212 amino acid residues ( Figure 3 ). After removal of a short secretory sequence, greatest significance in cardiovascular regulation. Hence, endothelin-1 is the major focus of this review.
proendothelin-1 undergoes cleavage by a dibasic pair specific endoprotease-probably furin-to generate the 38 aminoWithin the human genome, the endothelins are each represented by a separate gene encoding a specific precursor acid peptide, 'big endothelin-1' [6] . Subsequent conversion to the mature, biologically active peptide, endothelin-1, for the mature isoform [13] . In the 5∞ flanking sequence there are binding sites for activating protein-1 and nuclear occurs through the action of endothelin converting enzymes (ECE-1 and ECE-2). This family of metalloprotease enzymes factor 1 through which angiotensin II and transforming growth factor b act respectively to induce endothelin-1 is related to neutral endopeptidase-24.11 (NEP) and the Kell protein but unrelated to angiotensin converting enzyme. expression. There are also binding sites for acute phase reactants which may mediate the effects of acute physiologi-ECE-1 [14] appears to be the physiologically active ECE and, by alternative gene splicing, it exists in two different cal stress. In the 3∞ region there is a sequence regulating selective destabilisation of preproendothelin-1 mRNA, possisoforms-ECE-1a and ECE-1b-with functionally distinct roles and tissue distributions. ECE-1a appears to be an ibly accounting for its short half-life. These sites serve as potential mechanisms for regulating production of endothelin intracellular enzyme expressed in the , so that concentrations are likely to be substantially higher at the interface between endothelial and vascular can convert extracellular big endothelin-1 to mature endothelin-1 [15] . ECE-1 and ECE-2 are both inhibited by smooth muscle cells than in blood, consistent with a primarily local action. In addition, the half-life of phosphoramidon, a combined ECE/NEP inhibitor but not by the selective NEP inhibitor, thiorphan, or by the ACE endothelin-1 in blood is short, at less than 5 min, with clearance predominantly via receptor binding and metabolism inhibitor, captopril. Both enzymes are selective for big endothelin-1, raising the possibility that other ECEs with in the lungs and kidneys [17] . selectivity for big endothelin-2 and -3 will be identified. Through prevention of the generation of the endothelins, Endothelin receptors ECE-1 must be a potential target for drug treatment.
The gene encoding endothelin-1 can be detected in a The endothelins act on two receptor subtypes, ET A and ET B , characterized on the basis of their pharmacology wide variety of tissues, including the endothelial and smooth muscle cells of blood vessels, heart, lung, brain, kidney, (Table 1) . Endothelin-1 has a similar binding affinity for ET A and ET B receptors-in the nanomolar range -but has pancreas and spleen. The gene encoding endothelin-2 may also be found in the vascular endothelium, as well as a much higher binding affinity for the ET A receptor than endothelin-3. In contrast, endothelin-1 and endothelin-3 the smooth muscle of the large and small intestine, myocardium, stomach, kidney, placenta and uterus.
have equal affinity for the ET B receptor. Understanding of the function of endothelin receptors has been aided by the Endothelin-3 expression predominates in the brain but is also found in the lung, gastro-intestinal tract and kidney.
use of specific pharmacological agonists and antagonists. Endothelin-3 and sarafotoxin S6c are respectively~2000 Big endothelin-1, endothelin-1 and endothelin-3 are present in plasma at picomolar concentrations that are probably fold and~30 000 fold selective as agonists at the ET B receptor and BQ-123 and BQ-788 are selective antagonists insufficient to exert a direct influence on vascular tone. Endothelin-1 is generally thought to be a paracrine and respectively at ET A and ET B receptors. The human ET A and ET B receptors have been cloned and exhibit~60% autocrine mediator rather than an endocrine hormone. Indeed, endothelin-1 is largely secreted abluminally by homology. ET A receptor mRNA can be detected in many tissues, with the highest expression in aorta, heart and endothelial cells towards the adjacent vascular smooth muscle kidney. The ET A receptor predominates on vascular smooth upregulated; for instance, by ischaemia [24] , cyclosporin [25] and interleukin-1b [26] . muscle cells and is responsible for causing vasoconstriction in both large and small blood vessels [18] . It is also the major receptor subtype in the heart [19] . In contrast, ET A Developmental biology mRNA cannot be detected in the liver or endothelial cells [20] . The ET B receptor can be detected in endothelial and Gene defects affecting the endothelin system have been described for both animals and man. Gene knockouts for vascular smooth muscle cells and is predominantly found in brain, lung, kidney and aorta [21] . The ET B receptor on the preproendothelin-1 gene in mice cause lethal abnormalities affecting the development of craniofacial, cardiovascular endothelial cells modulates vasoconstriction in response to endothelin-1 through the production of vasodilator suband pharyngeal pouch structures [27, 28] . Interestingly, these abnormalities have also been found in teratogenicity studies stances including prostacyclin and nitric oxide. It is now widely recognised that the ET B receptors on vascular smooth during the pre-clinical development of a range of ET A receptor antagonists indicating, at least during development, muscle cells can mediate vasoconstriction, particularly in small resistance vessels and veins. The significance of the that endothelin-1 may be the natural ligand for the ET A receptor and that endothelin-1 has an important role in the vasoconstrictor ET B receptor will be discussed later. There has been a recent tendency to sub-classify the ET B receptor development of the pharyngeal arches, heart and great vessels. Indeed, it has been suggested that endothelin-1/ET A on the basis of responses to selective agonists and antagonists [22] but this currently cannot be justified on a molecular receptor anomalies may contribute to the Pierre-Robin and Treacher-Collins syndromes [29] . One anomalous finding basis.
The ET A and ET B receptors are classical heptahelical in these studies was the development of raised blood pressure in the endothelin-1 knockout mice. However, evidence is rhodopsin-like G-protein coupled receptors that activate phospholipase C leading to hydrolysis of phosphatidyl emerging that the elevation of blood pressure is related to sympatho-adrenergic overactivity caused by the severe inositol and generation of cytosolic inositol trisphosphate and membrane bound diacylglycerol [9] . Inositol trisphosphhypoxia that is a consequence of the facial/pharyngeal anomalies [29] . ate causes an early rapid rise in [Ca 2+ ] i through its release from intracellular stores. A more sustained rise of intracellular Both endothelin-3 and ET B receptor mutations lead to the formation of aganglionic megacolon and coat pigmencalcium occurs through opening of membrane Ca 2+ channels. Diacylglycerol activates protein kinase C, increastation anomalies in animals [30] . In this case, genetic abnormalities of either the preproendothelin-3 gene or the ing sensitivity of the contractile apparatus to Ca 2+ , activates nuclear signalling mechanisms -with possible effects on ET B receptor have been documented in congenital neurocristopathies associated clinically with Hirschsprung's disease long term regulation of cellular function-and causes a rise in the intracellular pH through an effect on the sodium- [31] and the Waardenberg-Shah syndrome [32] . Hence, the interaction of endothelin-3 with the ET B receptor appears hydrogen ion exchange membrane pump. Endothelin-1 may also interact with the ATP-sensitive potassium channel, so to be important for the development of cells within the neural crest. contributing to the rise in [Ca 2+ ] i . In addition, it may activate phospholipase A 2 , increasing production of arachidonic acid, and hence of prostacyclin (PGI 2 ) and thromboxCardiovascular pharmacology ane A 2 [10] .
The endothelins bind tightly to their receptors in a Bolus administration of endothelin-1 is known to cause a marked pressor effect lasting for more than 60 min [6] in 'pseudo-irreversible' manner and the endothelin-receptor complex is rapidly internalized. Slow dissociation from contrast to the brief effects of all other endogenous vasoconstrictor substances. Despite rapid clearance of the their receptors may account for prolonged actions of the endothelins. Endothelin receptor expression is itself regulated peptide from blood, this sustained pressor effect has been confirmed from studies in man [33, 34] , and is mediated by exposure to endothelin-1 so that agents that enhance endothelin-1 production, such as angiotensin II and certain predominantly through an increase in peripheral vascular resistance. The pressor effect tends to reduce cardiac output growth factors, can cause endothelin receptor downregulation [23] . In contrast, endothelin receptor number can be
[35], probably through a baroreceptor mediated decrease in heart rate, although an increase an afterload may possibly that endothelin-1 responses in human veins depend only in part on Ca 2+ entry through dihydropyridine-sensitive Ca 2+ contribute. Coronary vasoconstriction is recognised to occur in humans who are bitten by the burrowing asp, Actractaspis channels. In addition, the greater efficacy of K ATP channel opening agents is consistent with endothelin-1 acting to engaddensis, the venom of which contains sarafotoxins [36] and the coronary vasoconstrictor effect of the endothelins close K ATP channels, causing plasma membrane depolarisation and vasoconstriction by mechanisms additional to has more recently been confirmed in healthy subjects [34] . It is also known that after bolus administration in animals, opening of voltage-operated Ca 2+ channels.
endothelin-1 causes transient hypotension associated with systemic vasodilatation through stimulation of the endothelial Cardiovascular physiology ET B receptor. However, such studies require high doses of endothelin-1 and, because endothelin-1 preferentially causes
Although studies with agonists are of considerable interest, when a mediator is not a classical circulating hormone the vasoconstriction in the renal, cardiac and cerebral circulations, such studies should clearly be avoided in man.
results can be frankly misleading and studies with antagonists are likely to be considerably more informative. One way to address directly the potential vasoconstrictor and dilator effects of the endothelins in vivo in man is to
The first endothelin 'antagonist' described was the ECE inhibitor, phosphoramidon [45] , and we decided to begin combine bilateral forearm blood flow measurements with unilateral brachial artery infusion of vasoactive drugs at our investigation in the forearm. However, to determine a dose that would inhibit ECE we first had to examine subsystemic, locally active doses. Because forearm muscle blood flow is only~50 ml min −1 compared with a cardiac responses to big endothelin-1. Brachial artery administration of big endothelin-1 caused a dose-dependent forearm output of~5000 ml min −1 substantial local effects can be achieved without a systemic action. By avoiding confounding vasoconstriction that could be blocked completely by phosphoramidon (30 nmol min −1 ), suggesting that the effects on organs such as the brain, kidney and heart, as well as potential influences on neurohumoral reflexes, vascular effects of the precursor are mediated through conversion to the mature peptide by ECE [46] . The blockade of responses can be attributed to a direct effect of the drug, providing a powerful, reproducible and safe method of constriction to big endothelin-1 by phosphoramidon is unlikely to have been due to inhibition of endothelin directly assessing vascular responses in vivo [37, 38] . Importantly, the responses obtained are also broadly predicreceptor binding, because vasoconstriction to endothelin-1 was unaffected by phosphoramidon and because conversion tive of those seen in the systemic and coronary circulation [38] .
to endothelin-1 and its C-terminal fragment was confirmed in plasma samples taken from the veins draining the infused Continuous infusion of endothelin-1 into the brachial artery causes a slowly developing dose-dependent reduction forearm [47] . Also, because circulating blood exhibits little ECE activity [48] , conversion of big endothelin-1 in the in forearm blood flow, with vasoconstriction sustained for more than 2 h after halting the infusion [8] . When given forearm presumably occurs via vascular, probably endothelial, ECE situated within the forearm resistance vessels. The via the brachial artery, low doses of the ET B selective agonists, endothelin-3 and sarafotoxin S6c, also produce difference in potency between big endothelin-1 and endothelin-1, and the ratio of C-terminal fragment to big vasoconstriction in human resistance vessels in vivo, consistent with vascular ET B receptors mediating at least part of the endothelin-1 in venous blood, both indicated that local ECE converts about 10% of luminally presented big ET-1 to functional response to endothelin-1 in these vessels [39] . In human blood vessels in vitro, threshold concentrations of ET-1, consistent with~10% conversion of exogenous big ET-1 by cells expressing the ECE-1 gene [14] . Big endothelin-1 potentiate contractions to noradrenaline [40] . However, a peripheral interaction of endothelin-1 with the endothelin-1 does not cause venoconstriction in hand veins [49] , even though these vessels respond to endothelin-1 [8], sympathetic nervous system has not been demonstrated in forearm resistance [41] or cutaneous capacitance vessels [42] suggesting that ECE activity may not be present in all vessel types. of healthy subjects in vivo. Endothelin-1 and endothelin-3 [39], and sarafotoxin S6c (unpublished observations), can Administration of phosphoramidon (30 nmol min −1 ) alone [46] resulted in a slowly progressive vasodilatation produce transient forearm vasodilatation, the dilator response to endothelin-3 and sarafotoxin S6c being greater and more (Figure 4 ), consistent with a role for endothelin-1 in maintenance of basal vascular tone. Although phosphoramiprolonged than that to endothelin-1 consistent with involvement of the endothelial ET B receptor. However, vasodilatdon is an imperfect tool, because it also acts as an inhibitor of NEP, this latter action is unlikely to explain the ation to the endothelins occurs only at high doses on bolus administration, suggesting that this is not a physiological vasodilatation because potent and selective inhibitors of NEP cause slowly progressive forearm vasoconstriction [46] response [39] . In human hand veins [43] , vasoconstriction is modulated predominantly by stimulated release of dilator (Figure 4 ). This effect of NEP inhibitors is likely to be caused by accumulation of a vasoconstrictor agent which prostaglandins.
Endothelin-1 and sarafotoxin S6c both cause sustained may be endothelin-1, because it is a substrate for metabolism by NEP and the vasoconstriction is not blocked by an ACE constriction of human dorsal hand veins in vivo [8, 39] , suggesting that both vascular ET A and ET B receptors can inhibitor. This observation may also account for the increase in plasma endothelin by NEP inhibitors in clinical trials [50] contribute to venoconstriction to endothelin-1 in humans. Venoconstriction in vivo is blocked more effectively by the and their failure to lower blood pressure in hypertensive subjects. K ATP channel opener, cromakalim, than the Ca 2+ channel antagonist, nicardipine or by hydralazine [44] , suggesting Confirmation that endogenous endothelin-1 generation contributes to the maintenance of basal tone in forearm component of the response might be reduced in conditions associated with endothelial dysfunction (see later). resistance vessels of healthy human subjects came from studies with the cyclic pentapeptide ET A receptor selective
Interestingly, vasoconstriction appears to be mediated solely by ET A receptors in the human skin microcirculation, again antagonist, BQ-123 [51], and the cyclic hexapeptide combined ET A/B antagonist TAK-044 [52] , given via the on the basis of studies with antagonists [57] .
Responses of the forearm resistance vessels to drugs given brachial artery. Both agents caused a progressive vasodilatation of the forearm vessels [46, 53] . The substantial effect into the brachial artery are usually predictive of the responses in the major resistance beds that serve to regulate blood of BQ-123 (Figure 4) suggests that vasoconstriction to endothelin-1 is mediated mainly through the ET A receptor pressure [38] . Indeed, for the l-arginine-nitric oxide system, the substantial-and at the time unexpected-reduction of on vascular smooth muscle. Subsequent studies have confirmed this effect of BQ-123, and shown that it can be forearm blood flow associated with administration of the nitric oxide synthase inhibitor, l-N G -monomethyl-arginine achieved with lower doses and when given for a shorter period [54] . Together, the l-arginine/nitric oxide system, (l-NMMA) [58] , predicted the substantial increase in peripheral vascular resistance that would be associated with the sympathetic nervous system and the endothelin system are currently the only mediator systems known to maintain systemic administration [59] . Similar predictions, though for an opposite effect, were made for systemic endothelin basal vascular tone. It now remains to be shown how the endothelin system is regulated, though this is likely to be receptor antagonism based on the data with BQ-123. These predictions were confirmed recently in healthy subjects [53] predominantly at a local level.
The greater effect of BQ-123 than a substantial local dose with another peptide drug, TAK-044, which is currently in clinical development. of TAK-044 would be consistent with a mainly dilator role for the ET B receptor. Further and more direct support for TAK-044, which functionally inhibits both ET A and ET B mediated responses [52, 60] , was given to healthy subjects this view comes from recent arterial experiments with an ET B selective inhibitor, BQ-788 [55] . This agent causes at a range of doses from 10-1000 mg systemically and was generally well tolerated [53] . A 15 min intravenous infusion progressive forearm vasoconstriction in healthy subjects [56] , consistent with greater functional importance of the dilator of TAK-044 at the highest dose of 1000 mg reduced systolic blood pressure by~4%, diastolic blood pressure by~18%, than the constrictor ET B receptor under physiological circumstances. On this basis, a proportion of the dilator and systemic vascular resistance by~26% over a 24 h period ( Figure 5 ), suggesting that a major part of the effect of response to BQ-123 is likely to be mediated by nitric oxide and prostacyclin acting through the unopposed endothelial TAK-044 is mediated in the resistance vessels. At this dose, but not consistently at lower doses, the major haemodynamic ET B receptor. It might also be anticipated that this Heart Association.
effect on systemic vascular resistance was accompanied by a pharmacokinetic parameters do not always predict the pharmacodynamic activity achieved. compensatory increase in cardiac output and heart rate. The substantial and long lasting effect of TAK-044 on systemic vascular resistance is even more remarkable considering the Cardiovascular pathophysiology short half life of this peptide in the circulation and confirms that endogenous endothelin generation is critical for cardioThere are a number of mechanisms whereby endothelin-1 may be involved in cardiovascular disease, for vascular homeostasis and control of blood pressure, as originally proposed by Yanagisawa [6] .
instance: reduced production in congenital cardiac anomalies; enhanced production in congestive heart disease; reduced Systemically administered TAK-044 also abolished the vasoconstriction to endothelin-1 infused via the brachial receptor number or affinity in Hirschsprung's disease; enhanced receptor number or affinity with cyclosporin artery for up to 3 h [53] but inhibited responses only partially at 8 and 12 h (unpublished data). Such studies can treatment; reduced peptide clearance in chronic renal failure; and an unopposed action with endothelial dysfunction confirm the efficacy of endothelin receptor antagonists and determine the duration of their action. This appears to be affecting the l-arginine/nitric oxide systems, which may be a factor in Raynaud's disease. Given the potentially beneficial especially important for this class of drug, where standard effects of nitric oxide to cause vasodilatation, and inhibit from animal models [67] . A recent report that the ET A receptor antagonist, BQ-123, substantially improved platelet aggregation and vascular growth, and the potentially adverse effects of endothelin-1 to promote vasoconstriction 12-week survival from 43 to 85% in a coronary occlusion model of CHF [68] as well as haemodynamic function and and vascular growth it is of considerable interest that many of the conditions associated with endothelial dysfunction cardiac remodelling is, therefore, very promising for the clinical developments in this area. Also, interestingly, raised causing reduced nitric oxide production, including atherosclerosis [61, 62] , are further compounded by increased plasma endothelin concentrations appear to be an extremely powerful predictor of 1 year mortality after acute myocardial production of endothelin-1. Indeed, it is clear that these systems do not function independently. Endothelin-1 generinfarction [69] .
Neurohumoral activation and tissue hypoxia should ation is enhanced by a range of other constrictor and growth promoting substances and inhibited by dilators including increase endothelin-1 production, and the actions of endothelin-1-vasoconstriction, co-mitogenesis, leading to nitric oxide (Figure 3) . Conversely, endothelin-1 promotes the production of nitric oxide but may also account for cardiac and vascular hypertrophy, enhancement of reninangiotensin and sympathetic nervous system activity, and some of the vasoconstriction that accompanies its inhibition by l-NMMA and clinically for the development of tolerance promotion of renal vasoconstriction and sodium retentionare all consistent with the circulatory abnormalities found in to exogenous nitrate administration [63] .
As well as having direct effects on vascular tone, this condition. Indeed, plasma endothelin concentrations are elevated in CHF, mainly through an increase in plasma big endothelin-1 may enhance vascular tone indirectly: by augmenting vasoconstriction to other agents, such as endothelin-1 [70] , consistent with increased synthesis, rather than decreased clearance, of endothelin-1. Plasma immunoangiotensin II, noradrenaline, serotonin; by enhancing central and peripheral sympathetic function; and by activating reactive endothelin correlates with the degree of haemodynamic [71] and functional impairment [72] in CHF, is the renin-angiotensin system. Endothelin-1 is also a co-mitogen, enhancing cell division and proliferation, gene associated with a worse prognosis-irrespective of the cause of the cardiac failure-and predicts mortality or the need expression, protein synthesis and, ultimately, promoting hypertrophy of vascular smooth muscle, as well as cardiac for cardiac transplantation [73] . Currently, measurement of plasma big endothelin-1 concentration is the best available myocytes and fibroblasts [64, 65] . Thus, endothelin-1 may serve to amplify vasoconstriction through the development predictor of outcome in CHF [74] . Interestingly, changes in plasma immunoreactive endothelin reflect the clinical of vascular hypertrophy.
There is a growing literature [10, 11] in support of a role response to the b-adrenoceptor blocker carvedilol in patients with CHF [75] , although it is not clear whether the drug is for endothelin-1 in the pathophysiology of a wide range of cardiovascular diseases. These include ischaemic heart disease producing its benefits through direct inhibition of the endothelin system or by an effect on cardiac performance. and atherosclerosis, as well as conditions associated with either sustained vasoconstriction-including hypertension,
In the first clinical trial of an endothelin antagonist in CHF [12] , in patients withdrawn from ACE inhibitor chronic heart failure, chronic renal failure, primary pulmonary hypertension-or with intermittent vasospasm-includtreatment, acute intravenous administration of the combined ET A/B antagonist, bosentan, increased cardiac output and ing Raynaud's disease, subarachnoid haemorrhage and acute renal failure. Hereafter, the review will focus on the reduced systemic and pulmonary vascular resistance without inducing reflex tachycardia or increasing plasma concenconsiderable body of evidence implicating the endothelin system in chronic heart failure and suggesting that it may be trations of angiotensin II or noradrenaline ( Figure 6 ). These beneficial haemodynamic effects of inhibition of the a suitable target for therapeutic intervention.
endothelin system are similar to those associated with ACE inhibition, and beg the question whether they would add Chronic cardiac failure to the effects of optimal treatment with an ACE inhibitor [76] . Studies with local brachial artery administration of the Chronic heart failure (CHF) is a common, disabling condition that causes substantial morbidity and mortality, ECE inhibitor, phosphoramidon, and the ET A receptor antagonist, BQ-123, have addressed this issue in patients and is a major consumer of health service resources [66] . This complex condition is associated with stimulation of with CHF [77] . Even though these patients were maintained on ACE inhibitors, both agents caused substantial vasodilatcompensatory neurohumoral reflexes, including effects on the renin-angiotensin and sympathetic nervous systems, that ation of the forearm resistance vessels, predicting that endothelin receptor antagonists might have additional value serve to maintain perfusion pressure but also act to increase peripheral vascular resistance, renal sodium reabsorption and in the treatment of CHF. Indeed, from recent studies, it does appear that the beneficial haemodynamic effects of cardiac workload. This leads to a 'vicious circle' of declining cardiac function and provides a rationale for the current bosentan occur in the presence of ACE inhibitors and are sustained on chronic oral treatment (W. Kiowski; personal mainstay of treatment, which is vasodilator therapy with ACE inhibitors. Although current treatment regimens are communication).
In local infusion studies, the vasoconstriction to undoubtedly successful, CHF still carries a substantial morbidity and mortality [66] and there is room for additional endothelin-1 was reduced in CHF patients compared with matched control subjects in both resistance vessels [77] and therapeutic manoeuvres.
The now well documented reduction in mortality with hand veins [78] consistent with increased endothelin-1 generation. In contrast, vasoconstriction to the selective ACE inhibitors in patients with CHF and left ventricular dysfunction after myocardial infarction [66] was predicted ET B receptor agonist, sarafotoxin S6c, was enhanced. These observations are also seen in the coronary vessels in ists in essential hypertension, congestive heart failure, primary pulmonary hypertension, subarachnoid haemorrhage, stroke experimental CHF [79] and ET B receptors are also upregulated in human CHF [80] , consistent with widespread and acute ischaemic renal failure. However, there are a number of other issues for pharmaceutical companies to upregulation of the smooth muscle, and perhaps endothelial, ET B receptor in this condition. Enhanced constriction to consider including the existence of currently effective treatment (essential hypertension), the lack of a sufficiently sarafotoxin S6c may, at least in part, be due to endothelial dysfunction affecting responses mediated through the endopredictive model for the disease (angioplasty restenosis) and concerns over whether the market size is sufficiently large thelial ET B receptor and suggests that constrictor ET B may be of greater importance in some diseases than they are to justify the development (subarachnoid haemorrhage and primary pulmonary hypertension). There is obviously also a under physiological circumstances. Nevertheless, in patients with CHF, the response to arterial administration of the need to keep the overall budget for such compounds within reasonable bounds so companies need to be selective in their selective ET B antagonist, BQ-788, is vasoconstriction, suggesting that the dilator response predominates and that research programmes. Nevertheless, it can be expected that the role of endothelin antagonists will be explored in clinical selective ET A antagonists might, therefore, offer some advantages in this condition. studies in a number of these candidate diseases and it is likely-as, for instance, with the capacity of ACE inhibitors to delay the progression of renal failure-that some of the Unresolved issues potential uses of endothelin antagonists cannot easily be anticipated at this stage. For instance, the potential anti-A number of major issues concerning endothelin antagonists remain unresolved. The first and most important of these is mitogenic action of endothelin antagonists may be critical in heart failure [68] and perhaps also in conditions like the choice of the appropriate therapeutic target. On purely scientific grounds there would certainly be sufficient essential and pulmonary hypertension, and may even be relevant for cancer therapy [81] . justification for clinical investigation of endothelin antagon-Although the first effective 'endothelin antagonist' was an selective ET A or combined ET A/B receptor antagonists would be more effective. ECE inhibitor there appear to have been few recent developments in this area. All of the four or more endothelin
The discovery of endothelin-1, and the design of endothelin antagonists, has been among the most promising antagonists in early clinical development, as well as at least 15 more in preclinical development [11] , are endothelin developments in cardiovascular medicine since the launch of ACE inhibitors 15 years ago. Major clinical trials are now receptor blockers. Most of these are orally active, although TAK-044 is a peptide and is therefore being developed for needed to confirm the predicted benefits for endothelin antagonists in patients with cardiovascular disease. indications requiring relatively brief administration. Some of these agents are combined ET A/B antagonists, whereas others The author's research in this area is currently supported by are selective ET A antagonists. There are currently no grants from the British Heart Foundation, High Blood selective ET B antagonists that are clearly intended for clinical Pressure Foundation, Scottish Office and The Wellcome development although it might be argued that they would Trust. Acknowledgement should also be given for the major produce an organ-selective effect in pulmonary hypertension, contributions to this work from research fellows in the avoiding systemic hypotension, given that hypoxic pulmonauthor's department, 
